Document is current
Any future updates will be listed below
-
Authors
Muz, Barbara
Azab, Feda
Fiala, Mark
King, Justin
Kohnen, Daniel
Fogler, William E.
Smith, Ted
Magnani, John L.
Vij, Ravi
Azab, Abdel Kareem
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA199092)
- License Information
-
More Information
Article History
Received: 19 December 2018
Revised: 7 April 2019
Accepted: 14 May 2019
First Online: 20 August 2019
Conflict of interest
: A.K.A. received research funding to partially support this study from GlycoMimetics Inc. Moreover, A.K.A. receives research support from Arch Oncology and Cantex Pharmaceuticals and is the founder and owner of Targeted Therapeutics LLC and Cellatrix LLC; however, these have no contribution to this study. W.E.F., T.S. and J.L.M. are employees and shareholders of GlycoMimetics Inc. The other authors declare that they have no conflict of interest.
